Irinotecan combined with bolus 5-fluorouracil and folinic acid Nordic schedule as first-line therapy in advanced colorectal cancer

Annals of Oncology

Volumn 13, Issue 12, 2002, Pages 1868-1873

  Glimelius, B ^a,b   Ristamaki R ^c   Kjaer, M ^d   Pfeiffer, P ^e   Skovsgaard, T ^f   Tveit, K M ^g   Linne T ^a   Frodin J E ^b   Boussard, B ^h   Oulid Aissa D ^h   Pyrhonen S ^c  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c TURKU UNIVERSITY HOSPITAL   (Finland)

^d AALBORG UNIVERSITY HOSPITAL   (Denmark)

^e ODENSE UNIVERSITY HOSPITAL   (Denmark)

^f KAS Herlev ^*  (Denmark)

^g ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^h SANOFI   (France)

Author keywords

Chemotherapy; Colorectal cancer; Irinotecan; Nordic schedule

Indexed keywords

ANTIBIOTIC AGENT; ATROPINE; COTRIMOXAZOLE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; LOPERAMIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ARTICLE; BOLUS INJECTION; CANCER GROWTH; CANCER SURVIVAL; CHOLINERGIC ACTIVITY; CLINICAL TRIAL; COLORECTAL CANCER; CONFIDENCE INTERVAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG INFUSION; DRUG RESPONSE; DRUG SAFETY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; HAND FOOT SYNDROME; HUMAN; LEUKOPENIA; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA AND VOMITING; NEUTROPENIA; NORWAY; PAIN; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; STOMATITIS; THROMBOCYTOPENIA; WORLD HEALTH ORGANIZATION;

EID: 0036924417     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdf324     Document Type: Article

References (19)

1. Advanced Colorectal Cancer Meta-Analysis Project. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. J Clin Oncol 1992; 10: 896-903.
2. Ragnhammar P, Hafström Lo, Nygren P et al. A systematic overview of chemotherapy effects in colorectal cancer. Acta Oncol 2001; 40: 282-308.
3. Creemers GJ, Lund B, Verweij J. Topoisomerase I inhibitors: topotecan and irinotecan. Cancer Treat Rev 1994; 20: 73-96.
4. Armand JP, Ducreux M, Mahjoubi M et al. CPT-11 (irinotecan) in the treatment of colorectal cancer. Eur J Cancer 1995; 31A: 1283-1287.
5. Cunningham D, Pyrhönen S, James RD et al. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 1998; 352: 1413-1418.
6. Rougier P, Van Cutsem E, Bajetta E et al. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 1998; 352: 1407-1412.
7. Saltz LB, Cox JV, Blanke C et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000; 343: 905-914.
8. Douillard JY, Cunningham D, Roth AD et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000; 355: 1041-1047.
9. Nordic Gastrointestinal Tumour Adjuvant Therapy Group. Biochemical modulation of 5-fluorouracil: a randomised comparison of sequential methotrexate, 5-fluorouracil and leucovorin versus sequential 5-fluorouracil and leucovorin in patients with advanced symptomatic colorectal cancer. Ann Oncol 1993; 4: 235-241.
10. Ristamäki R, Glimelius B, Linné T et al. A phase I/II of CPT-11 combined with 5-fluorouracil (5FU)/folinic acid (FA) Nordic schedule as first therapy in patients (pts) with metastatic colorectal cancer (MCRC). Ann Oncol 2000; 11 (Suppl 4): 201 (Abstr).
11. Maiello E, Gebbia V, Giuliani F et al. 5-Fluorouracil and folinic acid with or without CPT-11 in advanced colorectal cancer patients: a multicenter randomised phase II study of the Southern Italy Oncology Group. Ann Oncol 2000; 11: 1045-1051.
12. Rothenberg ML, Meropol NJ, Poplin EA et al. Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: summary findings of an independent panel. J Clin Oncol 2001; 19: 3801-3807.
13. Sargent DJ, Niedzwiecki D, O'Connell MJ et al. Recommendation for caution with irinotecan, fluorouracil, and leucovorin for colorectal cancer. N Engl J Med 2001; 345: 144-145.
14. Glimelius B, Jacobsen A, Graf W et al. Bolus injection (2-4 min) versus short-term (10-20 min) infusion of 5-fluorouracil in patients with advanced colorectal cancer: A prospective randomised trial. Eur J Cancer 1998; 34: 674-678.
15. Jakobsen A, Berglund A, Glimelius B et al. The dose effect relationship of bolus 5-fluorouracil in the treatment of advanced colorectal cancer. Acta Oncol 2002; 41: 525-531.
16. Poon MA, O'Connell MJ, Moertel CG et al. Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma. J Clin Oncol 1989; 7: 1407-1418.
17. de Gramont A, Bosset JF, Milan C et al. Randomised trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. J Clin Oncol 1997; 15: 808-815.
18. Weh HJ, Zschaber R, Braumann D et al. A randomised phase III study comparing weekly folinic acid (FA) and high-dose 5-fluorouracil (5-FU) with monthly 5-FU/FA (days 1-5) in untreated patients with metastatic colorectal carcinoma. Onkologie 1998; 21: 403-407.
19. Aranda E, Diaz-Rubio E, Cervantes A et al. Randomised trial comparing monthly low-dose leucovorin and fluorouracil bolus with weekly high-dose 48-hour continuous-infusion fluorouracil for advanced colorectal cancer: a Spanish Cooperative Group for Gastrointestinal Tumour Therapy (TTD) study. Ann Oncol 1998; 9: 727-731.